Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Fish and Richardson
Boehringer Ingelheim
Mallinckrodt
Argus Health
Julphar
AstraZeneca
McKinsey
Teva

Generated: October 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208383

« Back to Dashboard

NDA 208383 describes BEVYXXA, which is a drug marketed by Portola Pharms Inc and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. Additional details are available on the BEVYXXA profile page.

The generic ingredient in BEVYXXA is betrixaban. One supplier is listed for this compound. Additional details are available on the betrixaban profile page.
Summary for 208383
Tradename:BEVYXXA
Applicant:Portola Pharms Inc
Ingredient:betrixaban
Patents:10
Generic Entry Opportunity Date for 208383
Generic Entry Date for 208383*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 208383
Mechanism of ActionFactor Xa Inhibitors
Suppliers and Packaging for NDA: 208383
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BEVYXXA betrixaban CAPSULE;ORAL 208383 NDA Portola Pharmaceuticals, Inc. 69853-0201 69853-0201-1 1 BOTTLE in 1 CARTON (69853-0201-1) > 100 CAPSULE, GELATIN COATED in 1 BOTTLE
BEVYXXA betrixaban CAPSULE;ORAL 208383 NDA Portola Pharmaceuticals, Inc. 69853-0202 69853-0202-1 1 BOTTLE in 1 CARTON (69853-0202-1) > 100 CAPSULE, GELATIN COATED in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength40MG
Approval Date:Jun 23, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Jun 23, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Try a Free TrialPatent Expiration:Sep 15, 2020Product Flag?YSubstance Flag?YDelist Request?
Patented Use:PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS
Patent:➤ Try a Free TrialPatent Expiration:Sep 15, 2020Product Flag?YSubstance Flag?YDelist Request?
Patented Use:PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Argus Health
Boehringer Ingelheim
Merck
Cerilliant
Johnson and Johnson
Teva
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.